Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma
2014 ASH Annual MeetingSagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 302, “Final Results for the 1703 Phase Ib/II Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma,” presented by Paul G. Richardson, MD; abstract 84, “Safety and Efficacy of Daratumumab With Lenalidomide and Dexamethasone in Relapsed or Relapsed/ Refractory Multiple Myeloma,” presented by Torben Plesner, MD; and “A Phase Ib Dose Escalation Trial of SAR650984 (Anti–CD-38 mAb) in Combination With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma,” presented by Thomas G. Martin III, MD.
Related Videos
Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, ...
Sagar Lonial, MD, on the Phase III ASPIRE Trial
Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 79, “Carfilzomib...
James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center,...
Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380,
Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survi...
Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
